Search Results for: MUC1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
RFX5 regulatory factor X5
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
  • Bare lymphocyte syndrome (BLS) type2
RHD Rh blood group D antigen
  • Rhesus blood group biosynthesis
RPS24 ribosomal protein S24
  • L13a-mediated translational silencing of Ceruloplasmin expression
  • Peptide chain elongation
  • SRP-dependent cotranslational protein targeting to membrane
  • SRP-dependent cotranslational protein targeting to membrane
  • Viral mRNA Translation
  • Selenocysteine synthesis
  • Major pathway of rRNA processing in the nucleolus and cytosol
  • Translation initiation complex formation
  • Formation of a pool of free 40S subunits
  • Formation of the ternary complex, and subsequently, the 43S complex
  • Ribosomal scanning and start codon recognition
  • GTP hydrolysis and joining of the 60S ribosomal subunit
  • Eukaryotic Translation Termination
  • Regulation of expression of SLITs and ROBOs
  • Response of EIF2AK4 (GCN2) to amino acid deficiency
  • SARS-CoV-1 modulates host translation machinery
  • SARS-CoV-2 modulates host translation machinery
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA
  • ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA
  • Diamond-Blackfan anemia (DBA)
RTP2 receptor transporter protein 2
  • Expression and translocation of olfactory receptors
SCAMP5 secretory carrier membrane protein 5
SEC22B SEC22 homolog B, vesicle trafficking protein
  • ER-Phagosome pathway
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • COPI-dependent Golgi-to-ER retrograde traffic
SELENOK selenoprotein K
SERP2 stress associated endoplasmic reticulum protein family member 2
SFTPC surfactant protein C
  • Surfactant metabolism
  • Defective pro-SFTPC causes SMDP2 and RDS
  • Defective CSF2RB causes SMDP5
  • Defective CSF2RA causes SMDP4
  • Pulmonary surfactant metabolism dysfunction (SMDP)
SIGLEC1 sialic acid binding Ig like lectin 1
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Beta-D-Glucose
  • N-acetyl-alpha-neuraminic acid
SLC22A1 solute carrier family 22 member 1
  • Neurotransmitter clearance
  • Norepinephrine Neurotransmitter Release Cycle
  • Abacavir transmembrane transport
  • SLC-mediated transport of neurotransmitters
  • SLC-mediated transport of organic cations
  • Ciprofloxacin ADME
SLC30A8 solute carrier family 30 member 8
  • Insulin processing
  • Zinc efflux and compartmentalization by the SLC30 family
  • Type II diabetes mellitus
SLC35B4 solute carrier family 35 member B4
  • Transport of nucleotide sugars
SLC35E4 solute carrier family 35 member E4
SLC38A7 solute carrier family 38 member 7
SLC61A1 solute carrier family 61 member 1
SMCO4 single-pass membrane protein with coiled-coil domains 4
SMIM1 small integral membrane protein 1 (Vel blood group)
SOS1 SOS Ras/Rac guanine nucleotide exchange factor 1
  • SOS-mediated signalling
  • SOS-mediated signalling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Signalling to RAS
  • Signalling to RAS
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • NRAGE signals death through JNK
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • NCAM signaling for neurite out-growth
  • G alpha (12/13) signalling events
  • Activation of RAC1
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • MET activates RAS signaling
  • RET signaling
  • Interleukin-15 signaling
  • RAC1 GTPase cycle
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Potential therapeutics for SARS
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Signaling by LTK
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • RHOU GTPase cycle
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • GPER1 signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Degradation of CDH1
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib

Page 14 out of 16 pages